Claims for Patent: 10,799,517

Summary for Patent: 10,799,517

Title:	Oral composition of celecoxib for treatment of pain
Abstract:	The present invention relates to a stable oral liquid pharmaceutical composition of celecoxib or its pharmaceutically acceptable salts thereof. The celecoxib present in the compositions as described herein do not show any precipitation when subjected in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH 2.0, temperature of 37.degree. C..+-.0.5.degree. C. and under stirring at a speed of 50 rpm at least for 60 minutes. It also relates to the process of preparing and method of using said composition of celecoxib.
Inventor(s):	Baheti; Ankit (Indore, IN), Padhi; Bijay Kumar (Buguda, IN), Vakada; Supritha (Hyderabad, IN), Raghuvanshi; Rajeev Singh (Gurgaon, IN)
Assignee:	DR. REDDY'S LABORATORIES LTD (Hyderabad, Telangana, IN)
Application Number:	15/922,353
Patent Claims:	1. An oral pharmaceutical composition, comprising at least a 20% reduced dose of celecoxib relative to conventional celecoxib in 400 mg oral capsules and a medium chain glyceride, wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters: a. AUC(0-15 min) of at least about 10 ngh/mL; b. AUC(0-30 min) of at least about 80 ngh/mL; c. AUC(0-1 hr) of at least about 400 ngh/mL; d. AUC(0-2 hr) of at least about 1000 ngh/mL; e. AUC(0-t) of at least about 2000 ngh/mL; f. AUC(0-.infin.) of at least about 2000 ngh/mL; and g. Tlag of not more than 8 minutes. 2. The composition of claim 1, wherein said composition further comprises at least one pharmaceutically-acceptable excipient. 3. The composition of claim 1, wherein said composition comprises at least about 40% less celecoxib compared to conventional 400 mg oral celecoxib capsules. 4. The composition of claim 1, wherein said composition comprises at least about 55% less celecoxib compared to conventional 400 mg oral celecoxib capsules. 5. The composition of claim 1, wherein said composition comprises at least about 70% less celecoxib compared to conventional 400 mg oral celecoxib capsules. 6. The composition of claim 1, wherein said reduced dose of celecoxib is about 320 mg. 7. The composition of claim 3, wherein said reduced dose of celecoxib is about 240 mg. 8. The composition of claim 4, wherein said reduced dose of celecoxib is about 180 mg. 9. The composition of claim 5, wherein said reduced dose of celecoxib is about 120 mg. 10. The composition of claim 1, wherein said composition is in the form of a solution, suspension, emulsion or liquid mixture. 11. The composition of claim 1, wherein said composition further comprises at least one solubilizer in an amount of from about 10% to about 70% by weight, based on the total weight of the composition. 12. The composition of claim 1, wherein the medium chain glyceride is present in an amount of from about 5% to about 75% by weight, based on the total weight of the composition. 13. The composition of claim 1, wherein said composition further comprises at least one solvent in an amount of from about 20% to about 80% by weight, based on the total weight of the composition. 14. The composition of claim 1, wherein said composition is essentially free of precipitation inhibitors. 15. The composition of claim 1, wherein said composition has a pH of from about 3 to about 7. 16. The composition of claim 1, wherein said composition does not show any precipitation in Fasted-State Simulated Gastric Fluid (FaSSGF) at pH of 2.0, temperature of 37.degree. C..+-.0.5.degree. C. and under stirring at a speed of 50 rpm, when measured at 60 min. 17. A method of providing a human subject pain relief within 2 hours, comprising administering to the subject an oral composition comprising at least a 20% reduced dose of celecoxib relative to conventional celecoxib in 400 mg oral capsules and a medium chain glyceride, wherein said composition upon oral administration to a human subject under fasting conditions, provides at least one of the following pharmacokinetic parameters: h. AUC(0-15 min) of at least about 10 ngh/mL; i. AUC(0-30 min) of at least about 80 ngh/mL; j. AUC(0-1 hr) of at least about 400 ngh/mL; k. AUC(0-2 hr) of at least about 1000 ngh/mL; l. AUC(0-t) of at least about 2000 ngh/mL; m. AUC(0-.infin.) of at least about 2000 ngh/mL; and n. Tlag of not more than 8 minutes. 18. The method claim 17, wherein said reduced dose of celecoxib is sufficient to render the subject pain free within 2 hours of administering the composition. 19. The method of claim 17, wherein said pain is acute pain, migraine pain, cluster headache, neuropathic pain, post-operative pain, chronic lower back pain, herpes neuralgia pain, phantom limb pain, central pain, dental pain, neuropathic pain, opioid-resistant pain, visceral pain, surgical pain, bone injury pain, pain during labor and delivery, pain resulting from burns, sunburn pain, post-partum pain, angina pain, genitourinary tract-related pain, cystitis pain, arthritis pain, inflammation pain, osteoarthritis pain, juvenile rheumatoid arthritis pain, ankylosing spondylitis pain, or primary dysmenorrhea pain. 20. The method of claim 17, wherein said composition comprises at least about 40% less celecoxib compared to conventional 400 mg oral celecoxib capsules. 21. The method of claim 17, wherein said composition comprises at least about 55% less celecoxib compared to conventional 400 mg oral celecoxib capsules. 22. The method of claim 17, wherein said composition comprises at least about 70% less celecoxib compared to conventional 400 mg oral celecoxib capsules. 23. The method of claim 17, wherein said composition further comprises at least one pharmaceutically-acceptable excipient. 24. The method of claim 17, wherein said composition is in the form of a solution, suspension, emulsion, or liquid mixture. 25. The method of claim 17, wherein said composition is essentially free of precipitation inhibitors. 26. The method of claim 17, wherein said composition has a pH of from about 3 to about 7.